What You Ought to Know:
– Curve Biosciences, the Entire-Physique Intelligence™ firm, as we speak introduced it has raised $40M in Collection A funding led by Luma Group, with participation from First Spark Ventures, Techas Capital, Civilization Ventures, LifeX Ventures, and others.
– The funding shall be used to speed up the medical validation and commercialization of its platform for persistent illness monitoring.
Molecular Blueprint for Power Illness
Curve Biosciences is addressing the rising prices and growing prevalence of persistent ailments, asserting that enhancements in affected person monitoring are obligatory to appreciate the total optimistic affect of contemporary breakthroughs, akin to GLP-1s.
The corporate has developed the Entire-Physique Atlas™, which is described because the world’s largest assortment of manually curated tissue samples characterised by organ and illness state. By returning to this tissue-level organic fact, Curve is creating Entire-Physique Blood Exams™.
These assessments, powered by the corporate’s Entire-Physique Intelligence platform, anticipate persistent illness, information remedy choices, and align stakeholders together with sufferers, insurers, pharma, and docs.
“To boost the usual of persistent illness monitoring, we are actually introducing the primary Entire-Physique Intelligence platform with AI fashions skilled on our Entire-Physique Atlas and fueled by our Entire-Physique Blood Exams,” stated Ritish Patnaik, PhD, CEO and Co-Founding father of Curve Biosciences.
Government Management and Medical Actionability
The corporate has assembled a extremely skilled government staff with deep experience in creating superior blood assessments and precision medication options:
- Ritish Patnaik, PhD, CEO: Former enterprise growth at Genentech, specializing in AI, knowledge engineering, and precision testing.
- Nathan Hunkapiller, PhD, Chief Scientific Officer: Beforehand Head of R&D at Natera and GRAIL, the place he led the event of superior blood assessments for oncology and prenatal screening.
- Alice Chen, PhD, Chief Working Officer: Former Head of Product and Program Administration at GRAIL, the place she led technique for a multi-cancer early detection blood check.
- Chuba Oyolu, PhD, Chief Know-how Officer: Founding Scientist and Senior Web site Director at Counsyl, with experience in scaling superior blood assessments.
- Prof. Shan Wang, PhD, Chief Innovation Officer: Leland T. Edwards Professor at Stanford College, contributing over 300 publications and 70+ patents.
